Mar 11,2021

Incyte Announces Data from Multiple Programs Within its Oncology Portfolio Accepted for Presentation at the AACR Annual Meeting 2021

Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during Week 1 of the upcoming American Association for Cancer Research (AACR) Annual Meeting 2021, held virtually from April 10-15, 2021.

View Analyst & Ambassador Comments
Go to original news
Mar 11,2021

New service that reduces wait times to see a dermatologist

Skinopathy Inc., a Canadian medical technology company, is expanding and introducing a new service through its flagship platform, GetSkinHelp.com, that allows Ontarians to schedule virtual dermatology appointments within 24 to 72 hours. The Coronavirus has led to many new realities, one of them being that routine medical appointments are now more difficult to schedule than ever. Not only is the healthcare system being pushed to its limits, but people are generally avoiding hospitals and medical clinics.

PRODUCT

#telehealth

View Analyst & Ambassador Comments
Go to original news
Mar 16,2021

COTA, Inc. and Kite Collaborate To Expand the Use of Real-World Data To Drive Faster, Effective Treatments for Cancers

COTA, Inc., an oncology real-world data and analytics company, today announced a collaboration with Kite, a Gilead company, through which COTA’s real-world data will be used to accelerate Kite’s drug development pipeline. This approach will help inform decisions about future therapeutic applications for blood cancers while inspiring new ways of thinking about how clinical trials are designed.

COLLABORATION PARTNERSHIP

#r&d

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Mar 18,2021

Broward Health and Voluntis launch a new clinical evaluation program on digital therapeutics for metastatic breast cancer

Voluntis, a leader in digital therapeutics, announced today a collaboration with Broward Health, a public health system in the U.S. The partnership will focus on conducting a real-world evaluation of Oleena, a digital application that assists patients in managing their symptoms. As part of the collaboration, Oleena, a FDA-authorized digital therapeutic application developed by Voluntis for patients with cancer, will be provided to patients with HR+/HER2- metastatic breast cancer to support them in self-managing symptoms and side effects of their conditions and treatments

COLLABORATION PARTNERSHIP

#institution

#dtx

#rwe

View Analyst & Ambassador Comments
Go to original news
Mar 30,2021

How an AI tool predicts responses to cancer treatment

OncoHost has developed a first of its kind host response profiling platform (PROphet) for predicting responsiveness to cancer therapies. The Company's technology analyses proteomic changes in patient blood samples to detect signs of resistance to cancer therapies in real-time, enabling biomarker-guided treatment planning for physicians, target discovery for drug development and, ultimately, improved outcomes for patients.

View Analyst & Ambassador Comments
Go to original news
Mar 30,2021

2020 annual results in line with the roadmap, demonstrating the success the new strategy, and confirmed confidence in the plan

As part of the new strategic roadmap presented in March 2020, Voluntis is committed to establishing major partnerships with leading pharmaceutical companies to commercialize its digital therapeutics, with a priority on oncologyhis ambition led to the collaboration with Bristol-Myers Squibb, announced in March 2020, to develop digital therapeutic solutions for the management of cancer patients’ symptoms and their remote monitoring by healthcare professionals. This collaboration complements the portfolio of programs in development in oncology based on Theraxium Oncology, Voluntis’ platform for digital therapies in oncology.

View Analyst & Ambassador Comments
Go to original news
Apr 20,2021

Kaiku Health to develop digital patient monitoring for melanoma with leading global medicines company

Kaiku Health, the developer of digital health intervention platform in oncology, today announced it will develop digital patient monitoring and management for melanoma patients in collaboration with Novartis, a leading global medicines company. Kaiku Health and Novartis are now aiming to further improve the remote monitoring and support of these patients with the joint development of a therapy-specific module for patients receiving BRAF/MEK combination therapies for melanoma. Kaiku Health platform will also automatically notify the care team, if patients’ symptoms get worse during the treatment course. Patients can use Kaiku Health either as the mobile application, designed for their smartphones and tablets, or the web browser-based application on their computers.

COLLABORATION PARTNERSHIP

#r&d

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 20,2021

Vinehealth announces partnership with Prostate Cancer Research

Vinehealth announces it’s partnership with leading UK charity, Prostate Cancer Research whose mission is to provide a better future for men and their families. Prostate Cancer Research funds world-class scientists and their pioneering research into prostate cancer, working towards new breakthrough treatments. Together, they will work towards supporting people living with prostate cancer to access crucial information and research, as well as enabling them to better track, manage and understand their care through the Vinehealth digital app.

COLLABORATION PARTNERSHIP

#institution

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 20,2021

Vinehealth shortlisted for 2021 Europas 'Hottest Healthtech Startup of the Year'

Vinehealth shared that they have been shortlisted as one of the ‘Hottest Healthtech Startup of the Year’ in the Europas 2021. The Europas were founded in 2009, by Mike Butcher, editor-at-large at Techcrunch.

View Analyst & Ambassador Comments
Go to original news
Apr 27,2021

ORCHA report "Digital Health for Cancer Services' lists Vinehealth as top in 'best practice

ORCHA’s newly released report ‘Digital Health for Cancer Services’ details how digital health is being used in oncology, their findings show that only 24.7% of apps meet the minimum quality thresholds, a worryingly low amount. However, ORCHA was also able to showcase almost 50 apps that do meet the thresholds and listed their 5 ‘best practice’ examples with Vinehealth at the top of their list.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY